- (-%)
Source:
Provectus Biopharmaceuticals, Inc., a Delaware corporation incorporated in 2002 (together with its subsidiaries, Provectus or the Company), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (HXs). Our lead HX molecule is named rose bengal sodium (RBS).
Country | United States |
Headquarters | knoxville, tennessee |
Phone Number | (866) 594-5999 |
Industry | manufacturing |
CEO | Peter R. Culpepper |
Website | www.provectusbio.com |